Genus plc operates as an animal genetics company in North America, Latin America, rest of Europe, the Middle East, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Research and Development. It sells sows, boars, and semen to breed pigs with various characteristics for pork production under the PIC brand. The company also sells bull semen and embryos, which are delivered through artificial insemination to breed dairy and beef cattle with various characteristics for milk and beef production under the ABS, Genus, and Bovec brands. In addition, it offers semen sexing, in vitro fertilization, reproductive, and other technical services to farmers; and agricultural and agri-food consultancy services. Genus plc was incorporated in 1994 and is headquartered in Basingstoke, the United Kingdom.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Phone+44-1256-347100
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees2,900
OptionableNot Optionable
Genus (LON:GNS) Frequently Asked Questions
What is Genus' stock symbol?
Genus trades on the London Stock Exchange (LON) under the ticker symbol "GNS."
How often does Genus pay dividends? What is the dividend yield for Genus?
Genus announced a dividend on Thursday, September 6th. Investors of record on Thursday, November 15th will be given a dividend of GBX 17.90 per share on Friday, November 30th. This represents a dividend yield of 0.7%. The ex-dividend date of this dividend is Thursday, November 15th. This is a boost from Genus's previous dividend of $8.10. The official announcement can be viewed at this link. View Genus' Dividend History.
What price target have analysts set for GNS?
4 analysts have issued 12-month target prices for Genus' shares. Their forecasts range from GBX 1,800 to GBX 2,630. On average, they anticipate Genus' share price to reach GBX 2,357.50 in the next year. This suggests a possible upside of 6.6% from the stock's current price. View Analyst Price Targets for Genus.
What is the consensus analysts' recommendation for Genus?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genus in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Genus.
Has Genus been receiving favorable news coverage?
Media coverage about GNS stock has been trending somewhat positive this week, InfoTrie Sentiment reports. The research firm identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Genus earned a daily sentiment score of 0.9 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an impact on the stock's share price in the immediate future.
Who are some of Genus' key competitors?
Some companies that are related to Genus include 22nd Century Group (XXII), 4d Pharma (DDDD), Abattis Bioceuticals (ATTBF), Abcam (ABC), ABcann Global (ABCN), ABLYNX NV/ADR (ABLX), ABZENA/PAR VTG FPD 0.002 (ABZA), Acasti Pharma (ACST), Acrux (ACR), Actinium Pharmaceuticals (ATNM), Actinogen Medical (ACW), Almirall (LBTSF), Altimmune (ALT), Ampio Pharmaceuticals (AMPE) and Ampliphi Biosciences (APHB).
Who are Genus' key executives?
Genus' management team includes the folowing people:
- Mr. Karim Bitar, CEO & Exec. Director (Age 53)
- Mr. Stephen Wilson, Group Fin. Director & Exec. Director (Age 58)
- Dr. Jonathan Lightner, Chief of R&D and Scientific Officer
- Mr. Dan Hartley, Group Gen. Counsel & Company Sec.
- Ms. Angelle R. Rosata, Group HR Director
How do I buy shares of Genus?
Shares of GNS and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Genus' stock price today?
One share of GNS stock can currently be purchased for approximately GBX 2,212.
What is Genus' official website?
How can I contact Genus?
Genus' mailing address is Matrix House, Basing View, BASINGSTOKE, RG21 4DZ, United Kingdom. The company can be reached via phone at +44-1256-347100.
MarketBeat Community Rating for Genus (LON GNS)
MarketBeat's community ratings are surveys of what our community members think about Genus and other stocks. Vote "Outperform" if you believe GNS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GNS will underperform the S&P 500 over the long term. You may vote once every thirty days.
